AG 825 manufacturers
- AG-825
-
- $30.00
-
2026-07-27
- CAS:149092-50-2
- Purity: 99.52%
- Supply Ability: 10g
- AG-825
-
- $30.00
-
2026-07-27
- CAS:149092-50-2
- Purity: 99.52%
- Supply Ability: 10g
|
| Product Name: | AG 825 | | Synonyms: | TYRPHOSTIN AG 825;TYRPHOSTIN C15;AG 825;5-[(BENZTHIAZOL-2-YL)THIOMETHYL]-4-HYDROXY-3-METHOXYBENZYLIDENECYANOACETAMIDE;5-[(BENZOTHIAZOL-2-YL)THIOMETHYL]-4-HYDROXY-3-METHOXYBENZYL-IDENECYANOACETAMIDE;4-HYDROXY-3-METHOXY-5-(BENZOTHIAZOLYLTHIOMETHYL)BENZYLIDENECYANOACETAMIDE;3-[3-[(2-Benzothiazolylthio)methyl]-4-hydroxy-5-methoxyphenyl]-2-cyano-
2-Propenamide;Tyrphostin C15, 5-[(Benzothiazol-2-yl)thiomethyl]-4-hydroxy-3-methoxybenzylidenecyanoacetamide | | CAS: | 149092-50-2 | | MF: | C19H15N3O3S2 | | MW: | 397.47 | | EINECS: | | | Product Categories: | Protein Kinase | | Mol File: | 149092-50-2.mol |  |
| | AG 825 Chemical Properties |
| storage temp. | −20°C | | solubility | DMSO: soluble | | form | Yellow solid | | color | Light yellow to yellow | | Sensitive | Light Sensitive | | InChI | 1S/C19H15N3O3S2/c1-25-15-8-11(6-12(9-20)18(21)24)7-13(17(15)23)10-26-19-22-14-4-2-3-5-16(14)27-19/h2-8,23H,10H2,1H3,(H2,21,24)/b12-6+ | | InChIKey | KXDONFLNGBQLTN-WUXMJOGZSA-N | | SMILES | COc1cc(cc(CSc2nc3ccccc3s2)c1O)\C=C(/C#N)C(N)=O |
| Safety Statements | 22-24/25 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | AG 825 Usage And Synthesis |
| Uses | A selective ErbB2 inhibitor | | Uses | AG 825 is a selective ErbB2 (Neu) inhibitor and apoptosis inducer. | | Definition | ChEBI: An organic sulfide that consists of 1,3-benzothiazole-2-thiol in which the hydrogen attached to the sulfur atom is replaced by a 5-[(1E)-3-amino-2-cyano-3-oxoprop-1-en-1-yl]-2-hydroxy-3-methoxybenzyl group. It acts as an epidermal growth
factor receptor antagonist. | | Biological Activity | Selective ErbB2 inhibitor (IC 50 values are 0.15 and 19 mM at ErbB2 and ErbB1 respectively). Preferentially triggers p38 MAP kinase-dependent apoptosis in androgen-independent prostate cancer cells. | | in vivo | AG-825 (20 mg/kg, i.p.) decreases peritoneal inflammation in Zymosan (HY-159069)-treated mice, and increases lung neutrophil apoptosis and macrophage efferocytosis in a murine acute lung injury model[4].
AG-825 (1 mg/kg, min-osmotic pump, 14 days) causes cardiac dilation and selective increase in β1AR density in mice[7].
| Animal Model: | Murine model of LPS induced acute lung inflammation[4] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Had no effect on percentage of, or absolute number of neutrophils or macrophages.
Increased the percentage of neutrophil apoptosis.
Elevated macrophage efferocytosis.
|
| Animal Model: | Murine model of Zymosan (HY-159069)-induced peritonitis[4] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Did not induce leukopenia.
Showed fewer inflammatory cells in peritoneal lavage.
Reduced the neutrophil chemoattractant and proinflammatory cytokine, KC.
Reduced IgM.
|
| | IC 50 | ErbB2: 0.35 μM (IC50); EGFR: 19 μM (IC50) | | storage | Store at +4°C |
| | AG 825 Preparation Products And Raw materials |
|